MOUNJARO 10MG PEN (Tirzepatide 10 mg)

Composition
Each prefilled pen contains Tirzepatide 10 mg as a sterile solution for subcutaneous injection.

Description
MOUNJARO 10 mg Pen is a long-acting antidiabetic injectable medicine used for the management of type 2 diabetes mellitus. Tirzepatide acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It improves glycaemic control by increasing insulin secretion in a glucose-dependent manner, reducing glucagon secretion, slowing gastric emptying and decreasing appetite, thereby supporting blood sugar control and weight management when used alongside diet and lifestyle modification.

Adverse Effects
Common adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal pain and reduced appetite, especially during the early phase of treatment. Injection site reactions such as redness, swelling or discomfort may occur. Hypoglycaemia may occur when used in combination with insulin or sulfonylureas.

Precautions
MOUNJARO is for subcutaneous use only and should not be administered intravenously or intramuscularly. Caution is required in patients with a history of pancreatitis, severe gastrointestinal disease or thyroid disorders. Dose escalation should be gradual to reduce gastrointestinal side effects. Use during pregnancy or breastfeeding should be only under medical advice. Regular monitoring of blood glucose is recommended during therapy.

Storage
Store refrigerated at 2°C to 8°C and protect from light. Do not freeze. After first use, store according to manufacturer’s instructions. Keep out of reach of children.